Eloxx Pharmaceuticals, Inc. (ELOX): Price and Financial Metrics


Eloxx Pharmaceuticals, Inc. (ELOX): $0.25

-0.02 (-7.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ELOX Stock Price Chart Interactive Chart >

Price chart for ELOX

ELOX Price/Volume Stats

Current price $0.25 52-week high $2.00
Prev. close $0.27 52-week low $0.21
Day low $0.25 Volume 122,900
Day high $0.28 Avg. volume 226,660
50-day MA $0.30 Dividend yield N/A
200-day MA $0.71 Market Cap 21.69M

Eloxx Pharmaceuticals, Inc. (ELOX) Company Bio


Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is based in Waltham, Massachusetts.


ELOX Latest News Stream


Event/Time News Detail
Loading, please wait...

ELOX Latest Social Stream


Loading social stream, please wait...

View Full ELOX Social Stream

Latest ELOX News From Around the Web

Below are the latest news stories about Eloxx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ELOX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!

William White on InvestorPlace | December 20, 2021

Eloxx Pharmaceuticals (NASDAQ:ELOX) Now Covered by Oppenheimer

Investment analysts at Oppenheimer began coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a note issued to investors on Thursday, Price Targets.com reports. The brokerage set an outperform rating and a $4.00 price target on the stock. Oppenheimers price target suggests a potential upside of 441.27% from the stocks previous close. ELOX has been the []

Transcript Daily | December 18, 2021

Millennium Management LLC Makes New Investment in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)

Millennium Management LLC acquired a new position in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 393,703 shares of the companys stock, valued at approximately $783,000. Millennium Management LLC owned approximately 0.82% of Eloxx Pharmaceuticals at the end of the []

Transcript Daily | December 13, 2021

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Expected to Announce Earnings of -$0.12 Per Share

Analysts expect that Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) will announce ($0.12) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Eloxx Pharmaceuticals earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.11). Eloxx Pharmaceuticals posted earnings per share of ($0.15) in the same []

Transcript Daily | December 11, 2021

State Street Corp Sells 248,516 Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)

State Street Corp reduced its holdings in shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) by 56.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 189,203 shares of the companys stock after selling 248,516 shares during the quarter. State Street Corps holdings in []

Transcript Daily | December 8, 2021

Read More 'ELOX' Stories Here

ELOX Price Returns

1-mo -19.82%
3-mo -54.60%
6-mo -60.03%
1-year -87.11%
3-year -97.43%
5-year -95.00%
YTD -64.60%
2021 -82.26%
2020 -45.92%
2019 -38.72%
2018 50.13%
2017 185.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4329 seconds.